Multiple Sclerosis
PracticeUpdate is guided by a world-renowned Editorial and Advisory Board that represents community practitioners and academic specialists with cross-disciplinary expertise.
Most Read This Week
- Differences in Treatment Outcomes Between Patients With MS Receiving Ocrelizumab and Those Receiving Ofatumumab
- Toward Personalized Dosing of B-Cell–Depleting Therapy
- Hypogammaglobulinemia and Severe Infections in Patients With MS on Anti-CD20 Agents
- Association Between a History of Head Trauma and the Risk of MS
- Risk of Hypertension in Patients With MS Treated With Teriflunomide vs Dimethyl Fumarate
Recently Updated
- Association of the Cervical Canal Area With Disability and Progression in People With MS
- Toward Personalized Dosing of B-Cell–Depleting Therapy
- Association Between a History of Head Trauma and the Risk of MS
- Differences in Treatment Outcomes Between Patients With MS Receiving Ocrelizumab and Those Receiving Ofatumumab
- Early Immunological and Metabolic Dysregulation of CD8+ T Cells in Patients With MS